REVIEW

Colorectal Cancer Disparity in African Americans

Risk Factors and Carcinogenic Mechanisms

Gaius J. Augustus* and Nathan A. Ellis^{†‡}

From the Cancer Biology Graduate Interdisciplinary Program,* the University of Arizona Cancer Center,[†] and the Department of Cellular and Molecular Medicine,[‡] University of Arizona, Tucson, Arizona

Accepted for publication
July 20, 2017.

Address correspondence to
Nathan A. Ellis, Ph.D., Department
of Cellular and Molecular
Medicine, or Gaius J. Augustus,
B.Sc., Cancer Biology Graduate
Interdisciplinary Program, University
of Arizona, 1515 N
Campbell Ave, Tucson, AZ
85724. E-mail: naellis@email.arizona.edu
or gaiusjaugustus@email.arizona.edu.

African Americans have the highest incidence and mortality rates of colorectal cancer (CRC) of any ethnic group in the United States. Although some of these disparities can be explained by differences in access to care, cancer screening, and other socioeconomic factors, disparities remain after adjustment for these factors. Consequently, an examination of recent advances in the understanding of ethnicity-specific factors, including genetic and environmental factors relating to risk of CRC, the biology of CRC progression, and the changes in screening and mortality, is important for evaluating our progress toward eliminating the disparities. An overarching limitation in this field is the number and sample size of studies performed to characterize the etiological bases of CRC incidence and mortality in African Americans. Despite this limitation, significant differences in etiology are manifest in many studies. These differences need validation, and their impacts on disparities need more detailed investigation. Perhaps most heartening, improvements in CRC screening can be attributed to the smallest difference in CRC incidence between African Americans and whites since the late 1980s. Cancer mortality, however, remains a persistent difference. (*Am J Pathol* 2018, 188: 291–303; <https://doi.org/10.1016/j.ajpath.2017.07.023>)

Colorectal cancer (CRC) is the third most common cancer in both men and women in the United States and the second most common cause of cancer-related death.¹ African Americans bear a disproportionate burden, with an incidence of CRC that is >20% higher than in whites and an even larger difference in mortality.² In particular, African Americans are more often diagnosed with CRC at an earlier age and with more advanced disease; and African Americans have a greater proportion of CRCs in the proximal colon.³ Although some of these differences can be explained by access to care, screening, and other socioeconomic factors, a significant portion of the disparity remains after adjustment for these factors.⁴ In this review, we examine the recent literature on genetic and environmental risk factors, molecular characteristics of CRC tumors, screening, and cancer-related mortality, and how these factors contribute to our understanding of the colorectal cancer health disparity in African Americans.

Impact of Risk Factors on CRC Incidence

Endoscopic Screening Reduces Cancer Incidence

Data from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute show that CRC incidence has been decreasing in recent years (Figure 1A). The change in CRC incidence is mostly attributed to increased endoscopic examination of the colorectum and the resulting removal of adenomatous and other polyps that are

Supported by National Cancer Institute grants U01 CA153060 and P30 CA023074 (N.A.E.) and the Cancer Biology Training grant T32 CA009213 (G.J.A.).

The content of this article is solely the responsibility of the authors and does not represent the official views of the NIH.

Disclosures: None declared.

This article is part of a review series on understanding the complex role of race in cancer health disparities.

Figure 1 **A:** Age-adjusted incidence rates of colorectal cancer (CRC) in African Americans (purple) and whites (green; explicitly non-Hispanic whites) from 1992 to 2014, all ages, both sexes [data from Surveillance, Epidemiology, and End Results (SEER) 13, Incidence—SEER 13 Regs Research Data, November 2016 Sub (1992 to 2014) <Katrina/Rita Population Adjustment>; <https://seer.cancer.gov/data/seerstat/nov2016>, accessed April 14, 2017]. Annual percentage change is depicted as text above data, where negative values indicate a decreasing trend and positive values indicate an increasing trend. **Asterisks** denote a rising or falling trend, where the entire 95% CI is above or below 0, respectively. **No asterisk** indicates a stable trend. **B:** Age-adjusted US mortality rates of CRC in African Americans (purple) and whites (green; explicitly non-Hispanic whites) from 1992 to 2014, all ages, both sexes (data from SEER 13). Annual percentage change is depicted as text above data, where negative values indicate a decreasing trend.

precancerous lesions.¹ The Surveillance, Epidemiology, and End Results program also reports trends that reflect annual percentage change of rates across certain time segments, which we have included above each corresponding segment. Whites have seen a decrease in CRC incidence since the 1990s. The incidence of CRC in African Americans began to decrease in the early 2000s. The incidence in the United States of CRC in African Americans was 26% higher than whites in 2013. The newest data from the Surveillance, Epidemiology, and End Results program show that African Americans have an 11% higher incidence than whites, the lowest difference since the

late 1980s. Although screening has clearly achieved substantial reductions in incidence, less than full compliance, early-onset CRCs, and missed lesions will resist further reductions; therefore, efforts to understand genetic and environmental risk factors continue to be important.

The increased risk of disease and cancer-related death in African Americans has led to changes in the screening recommendations in this population, specifically in lowering the age to begin colonoscopic screening to 45 years.^{5–7} Historically, African Americans have had lower compliance to CRC screening guidelines. Efforts to increase screening have resulted in an increase in compliance, which has been reviewed elsewhere.⁸ Increased colonoscopic screening in African Americans has been cited as a major reason for the recent decrease in incidence in this population² (Figure 1A).

Continued efforts to increase knowledge of new screening guidelines in African American communities are necessary. In addition, because patient follow-up is lower in African Americans after an abnormality is found, community-based support programs should be developed to improve follow-up rates.⁹ More important, access to screening options and affordable care are essential to decrease the burden of CRC faced by African Americans, and these barriers must be addressed by communities across the country.⁵

Genetic Risk Factors and CRC Incidence

It is estimated that genetic factors contribute as much as 35% to the overall risk of CRC.¹⁰ Our understanding of genetic risk factors is anchored in mendelian genetics (ie, in single-gene defects that are associated with a high risk of CRC development).¹¹ Mutations in the adenomatous polyposis coli (*APC*) gene are linked to familial adenomatous polyposis. *APC* mutations ablate a key factor in the regulation of the WNT signaling pathway (Figure 2). WNTs are a large family of secreted glycoproteins that regulate cell proliferation, differentiation, polarity, and migration.¹² In the adult intestine, WNTs control homeostasis by maintaining stem cell populations in the base of the crypts. In the canonical WNT signaling cascade, WNT stimulation prevents degradation of the transcription factor β -catenin by inhibition of the destruction complex. The destruction complex consists of the APC protein, axis inhibition protein, glycogen synthase kinase 3, and casein kinase 1 isoforms. In the absence of WNT, the complex mediates the phosphorylation of β -catenin, which targets β -catenin to the proteasome. In the presence of WNT, β -catenin degradation is inhibited; and it migrates into the nucleus, where it mediates the transcriptional activation of genes, such as *MYC* and cyclin D1. Biallelic mutation of *APC* is associated with failure to down-regulate β -catenin, causing overexpansion of the stem cell compartment and the development of an adenomatous polyp. Over time, adenomatous polyps can progress to carcinoma as other cancer driver mutations in genes, such as *KRAS*, *SMADs*, and *TP53*, arise in the polyp. Familial adenomatous polyposis is a classic autosomal

Recently, biallelic mutations in the base excision repair gene *MUTYH* have been associated with a recessive CRC polyposis syndrome. Base excision repair is a system that removes damaged bases in DNA, particularly oxidized guanine bases, followed by polymerase-associated insertion of the correct nucleotide and ligation. *MUTYH* specifically operates on lesions in which the oxidized guanine base had undergone DNA replication, resulting in an oxidized guanine/adenine mismatch. To prevent mutation, *MUTYH* protein initiates a repair event in which a cytosine base is inserted opposite the oxidized guanine base. In the absence of *MUTYH* function, this form of DNA repair is defective, and an increase in guanine-to-thymine mutations is the

Mutations in the mismatch repair (MMR) genes *MLH1*, *MSH2*, *MSH6*, and *PMS2* are associated with Lynch syndrome, which is the most common hereditary CRC syndrome, accounting for as much as 3% of all CRCs.¹¹ The MMR system removes mismatched bases that have been improperly incorporated into DNA during replication. Lynch syndrome is associated with a wide array of cancer sites, including the uterus, ovary, stomach, small intestine, bile ducts, ureter, and transitional cells in the kidney, brain, and skin.

Mutations in the *APC*, *MUTYH*, and MMR genes, together with several much less frequently mutated syndrome-causing genes, contribute to approximately 5% of all CRCs and constitute, at most, 40% of the total genetic variance in CRC

risk. In the past 10 years, there have been attempts to close the gap between mendelian genetics and the genetic variance that remains to be explained via the conduct of genome-wide association studies (GWASs). GWASs compare the frequencies of common genetic variation—single-nucleotide polymorphisms (SNPs)—in CRC cases versus controls to identify SNPs associated with disease. These studies were successful in the identification of many new CRC risk factors across the genome; however, the proportion of the genetic variance in CRC that is explained by these newly identified risk factors is, at most, 5%.¹⁴ The effect sizes of these common genetic risk factors are relatively small (odds ratios, from 1.04 to 1.56); consequently, large studies (samples sizes in the hundreds of thousands) may be required to identify all of the common genetic risk factors. Recent work also focuses on genetic variation that is less common (allele frequencies, <5%) and on gene-environment interactions that might explain the so-called missing genetic variance.

It is against this backdrop of the rare, the common, and the unknown that we will consider the current state of affairs in the understanding of genetic risk factors for CRC in African Americans. As expected, African Americans are not exempt from occurrence of the rare hereditary syndromes. Early evidence showed that African Americans with hereditary forms of CRC harbored novel mutations in the MMR genes.¹⁵ Recent clinic-based reports have gone further to detail many more genetic mutations in *APC* and *MUTYH*¹⁶ and in the MMR genes¹⁷ in the African American population. Differences in the numbers or proportions of hereditary cases identified in African Americans compared with whites most likely reflect differences in the ordering of genetic testing rather than differences in the frequencies or the phenotypes associated with these mutations, although more extensive investigation of these questions is needed. Population-based studies have not addressed questions relating to the frequency of mutations in the known hereditary genes in African American populations, so that we do not know the impact of hereditary mutations on the incidence of CRC in African Americans and on the disparity in incidence. In the white population, hereditary mutations account for approximately 5% of all CRCs; thus, the difference in frequency of hereditary mutations would have to be large to explain the difference in incidence. Moreover, there is evidence against a large excess of MMR gene mutations—the largest class of hereditary mutations—based on phenotypic testing of African American CRCs (discussed in *Similar Frequencies of Microsatellite Instability*).

GWASs have identified >40 risk-associated regions on the basis of analysis of SNP data generated predominantly in European-ancestry CRC cases compared with controls.¹⁸ Theoretically, a higher frequency of common genetic risk factors predisposing to CRC in African Americans may explain differences in incidence between whites and African Americans. However, taking into account the differences in allele frequencies and odds ratios between the two populations, there is substantially more attributable risk estimated for

the known risk-associated regions in European-ancestry populations compared with that in African Americans. This conclusion emanates from two studies, each including >1800 African American subjects, who were tested for replication of known risk-associated SNPs (Table 1). The studies found that slightly less than half of the known risk-associated regions were significantly associated with CRC in African Americans.^{19,20,22} African American populations have been included as part of larger GWASs (eg, in the identification of SNP associations in *VTGIA*).²³ Because patterns of linkage disequilibrium differ between European- and African-ancestry populations, associations with SNPs in African Americans that are different from the index SNP in European-ancestry populations have been observed in several instances. In addition, novel associations within known risk-associated regions have been reported.^{19,21} Finally, using a GWAS design, a novel CRC African American—specific association with the *SYMPK* gene was identified.²⁴

Lack of replication for European-ancestry SNP associations has also been observed in an Asian CRC GWAS.²⁵ Differences in allele frequencies and linkage disequilibrium structure between populations and population-specific gene-gene and gene-environment interactions have been proposed as explanations. Lack of adequate power to detect associations remains a problem in the African American GWASs. The observation of novel associations in which the risk-associated SNP is absent or present only at low frequencies in European-ancestry populations indicates the existence of population-specific or population-restricted risk alleles^{21,24}; many more of this kind of risk factor are likely to be encountered as investigations turn to alleles with frequencies of <5%. In summary, GWASs in African American CRC have uncovered a limited number of risk-associated regions, and additional GWASs are needed to fully explore the genetic architecture of CRC risk in African Americans. Analysis of risk alleles that have frequencies of <5% will face an additional obstacle from the higher frequencies of benign genetic variation in African-ancestry populations, making the distinction between signal and noise more challenging.

Can Vitamin D Levels Explain Differences in CRC Incidence in African Americans?

Vitamin D is a hormone; its production is initiated in basal keratinocytes in the skin as a result of exposure to UVB (280 to 320 nm) rays in sunlight. The cholecalciferol generated in the skin is converted to calcidiol in the liver, and calcidiol is converted to calcitriol, which is the active hormone, by the kidney and other tissues. Approximately 95% of the total vitamin D is produced endogenously as opposed to obtained through diet or dietary supplementation.²⁶ Vitamin D has numerous physiological effects, including regulation of calcium homeostasis, immunity, insulin secretion, and blood pressure and carcinogenesis. In case-control and cohort studies, higher levels of serum vitamin D are associated with a

Table 1 Associations Identified in Two Replication Studies that Tested for Association at Known Susceptibility Regions

Gene region*	Chr	SNP ID	Position, bp	Allele	F(A)	OR	P value	Ref	Notes
<i>LINC01655</i>	1q41	12759486	222,066,536	T	0.58	0.86	1.5×10^{-4}	19	Fine-mapping SNP
<i>C5orf66</i>	5q31.1	rs647161	134499052	A	0.55	1.14	0.002	19	Index SNP
<i>SLC22A3</i> [†]	6q26-27	rs7758229	160,840,252	T	0.11	1.08	0.056	19	Index SNP
<i>EIF3H</i>	8q23.3	rs16892766	117,630,683	C	0.13	1.17	0.0058	19	Index SNP
<i>EIF3H</i>	8q23.3	rs16892766	117,630,683	C	0.13	1.15	0.19	20	Index SNP
<i>MYC</i>	824.21	rs6983267	128,413,305	T	0.13	0.87	0.029	19	Index SNP
<i>MYC</i>	824.21	rs6983267	128,413,305	T	0.12	0.87	0.21	20	Index SNP
<i>MYC</i>	824.21	rs7014346	128,424,792	G	0.39	1.05	0.27	19	Index SNP
<i>MYC</i>	824.21	rs7014346	128,424,792	G	0.39	1.15	0.06	20	Index SNP
<i>POLD3</i>	11q13.4	rs3824999	74,345,550	G	0.20	1.15	0.009	19	Index SNP
<i>GREM1</i>	15q13.3	rs16969681	32,993,111	T	0.13	1.16	0.01	19	Index SNP
<i>GREM1</i>	15q13.3	rs10318	33,025,979	T	0.03	1.45	0.04	20	Index SNP
<i>GREM1</i>	15q13.3	rs11632715	33,004,247	A	0.38	1.04	0.34	19	Index SNP
<i>GREM1</i>	15q13.3	rs11632715	33,004,247	A	0.29	2.36 [‡]	0.004	20	Index SNP
<i>GREM1</i>	15q13.3	rs17816285	33,039,298	G	0.29	3.13 [‡]	2×10^{-4}	21	Novel SNP association
<i>CDH1</i>	16q22.1	rs9929218	68,820,946	A	0.29	0.93	0.12	19	Index SNP
<i>CDH1</i>	16q22.1	rs1862748	68,832,943	T	0.20	0.82	0.023	20	Index SNP
<i>RHPN2</i>	19q13.1	rs7252505	33,575,064	A	0.62	0.85	1.8×10^{-4}	19	Fine-mapping SNP
<i>RHPN2</i>	19q13.1	rs113984415	33,555,034	A	0.19	0.13	8×10^{-5}	21	Novel SNP association
<i>CASC20</i>	20p12.3	rs961253	6,404,281	A	0.36	1.08	0.054	19	Index SNP
<i>CASC20</i>	20p12.3	rs961253	6,404,281	A	0.37	0.93	0.30	20	Index SNP

The studies by Wang et al.¹⁹ and Kupfer et al.²⁰ included African American subjects comparing 1894 cases with 4703 controls and 795 cases with 985 controls, respectively. Wang et al.¹⁹ tested 21 risk-associated regions, and Kupfer et al.²⁰ tested 10 risk-associated regions. The two studies share a small subset of North Carolina subjects. Two novel associations were reported for *GREM1* and *RHPN2* in the study by Kupfer et al.²¹ Fine-mapping SNP is an SNP correlated with the index SNP that showed a stronger association *P* value. Unless otherwise stated, a log-additive model was used to estimate effect size and *P* value.

*Assignment of a gene to the association is based on proximity to the nearest risk-associated SNP.

[†]The association shown was observed for left-sided colorectal cancer only. No association was observed for all colorectal cancer.

[‡]Recessive model.

Allele, allele used as reference; Chr, chromosome; F(A), frequency of the reference allele; ID, identification; OR, odds ratio (not adjusted for local ancestry); *P* value, *P* value of association; Ref, article from which data were reproduced; SNP, single-nucleotide polymorphism.

lower frequency of CRC,^{27,28} and administration of vitamin D can suppress CRC in animal models.²⁹

Because cutaneous melanin absorbs UVB wavelengths, individuals with darker skin colors require more sun exposure to achieve equivalent levels of serum vitamin D than individuals with lighter skin colors.³⁰ One apparent consequence of this difference is that African Americans have substantially lower levels of serum vitamin D than their white counterparts, especially in northern parts of the United States. Consequently, it has been hypothesized that some part of the disparity in CRC incidence may be explained by lower vitamin D levels in African Americans.²⁷ In addition, lower vitamin D levels may also be associated with the higher rate of CRC-specific mortality in African Americans.^{31,32}

Because of the link between colorectal adenoma and CRC, one expectation of this hypothesis is that vitamin D levels should be inversely associated with adenoma occurrence, but the data in favor of this expectation have been inconsistent.^{33–35} Inverse association with vitamin D levels may be restricted to advanced adenomas,³⁶ which are more predictive of CRC risk. Another expectation is that supplementation with vitamin D should reduce the frequency of adenoma recurrence. Negative results from a large prevention trial, in which 1000 IU of vitamin D₃ was administered for 3 to 5 years, argue against a strong effect of vitamin D

supplementation on adenoma recurrence.³⁷ This prevention trial also challenged the commonly held view that calcium supplementation reduces adenoma recurrence, although the prevalence of obesity in the study population may have attenuated response. The study did not address whether longer periods or higher levels of supplementation would provide protection from CRC and the extent to which vitamin D reduces progression of CRC. Moreover, few African Americans, the population with the highest risk because of low levels of serum vitamin D, were included in it.

Evidence for a contribution to African American CRC of genetic risk factors in vitamin D pathway genes is mostly negative,^{38–40} consistent with the finding that genetic variance contributes little to the variance in total vitamin D levels.⁴¹ There is evidence that individuals with specific vitamin D receptor (*VDR*) genotypes might respond favorably to vitamin D supplementation and, by extension, to higher levels of vitamin D, whatever the source.⁴² Moreover, there are differences between African- and European-ancestry individuals in the transcriptional response of colonic epithelial cells to active vitamin D hormone administered *in vitro*, suggesting that ethnicity-dependent regulatory circuitry may play a role in response to vitamin D levels *in vivo*.⁴³ At a broader level, many of the genetic variants that are associated with differences in gene

expression levels in gut epithelial cells are population differentiated [as defined by a fixation index statistic (F_{ST}) > 0.25], suggesting that this genetic variation is subject to natural selection driven by local adaptations to the environment.⁴⁴

Dietary Influences on CRC and the Gut Microbiome

Migration studies strongly support a dominant role for environmental factors in the etiology of CRC.^{45,46} Populations migrating from countries with a low prevalence of CRC to countries with a high prevalence of CRC acquire the higher CRC prevalence of their new country within a generation or less. Individual dietary components are often credited for increasing (eg, red meat consumption) or decreasing (eg, fiber) CRC risk, but the evidence is uneven and relatively weak.^{47,48} For example, individuals in the highest quartile of red meat consumption have an approximately 40% increased risk of CRC over individuals in the lowest quartile.^{49,50} This association was observed in retrospective studies but was not significant in prospective studies. African Americans have been underrepresented in most studies; however, observations made in the North Carolina Colon Cancer Study and a sister study administered by the same group that included rectal cancer cases suggest that dietary patterns may explain some of the racial differences in CRC.^{51,52}

Recently, attention has turned to the gut environment, specifically its microbial communities, to better understand the interplay between dietary factors and host microbiota in the development of CRC. The gut microbiota consists of trillions of microbes, the vast majority of which are bacteria.⁵³ The term microbiome refers to the collective genome harbored by the microbiota. Microbiota–host interactions comprise a continuum of symbiosis, commensalism, and pathogenicity.⁵⁴ Growing evidence implicates biofilms and adverse species of adherent bacteria in the process of CRC development.⁵⁵ Broadly, there are three ways in which the microbiota may contribute to carcinogenesis⁵⁶: i) by acting as cancer-initiating microbes (oncomicrobes), ii) by guiding adverse immune system function, and iii) by producing carcinogenic metabolites. There is solid evidence for all three mechanisms, but the relative contribution of each is unknown.

Incidence rates of CRC are vastly different for African Americans (60 per 100,000 per year) and South African blacks (5 per 100,000 per year). Of the many differences that characterize the environment for these different individuals, diet can play an outsize role in the incidence rates for CRC. The diet for rural South African blacks is highly enriched in fiber and low in meat and fat, whereas the Western diet is low in fiber and high in meat and fat. O’Keefe and colleagues⁵⁷ conducted a diet switch in which they gave Pittsburgh African Americans the traditional South African black diet, whereas they gave rural South African blacks the Western diet. They then examined changes in the gut microbiome and fecal metabolites.

Reciprocal changes were observed in the gut microbiome and the metabolome within 2 weeks of diet switch. African Americans receiving the high-fiber, low-fat diet exhibited increases in the abundance of microbial species involved in fiber fermentation, including species that metabolize butyrate and other short-chain fatty acids and the hydrogenotrophic microbes that remove hydrogen, including methanogens, acetogens, and sulfate-reducing bacteria. Concomitantly, there was suppression of microbial species that process bile acids, including bile acid deconjugators and the pathogenic sulfidogenic bacteria *Bilophila wadsworthia* and *Fusobacterium nucleatum*. South Africans receiving the low-fiber, high-fat diet exhibited the opposite pattern (ie, a lower abundance of species engaged in saccharolytic fermentation and higher bile acid deconjugating species). In addition, there were also reciprocal changes in gut epithelial cell proliferation, which is a marker for cancer development. The secondary bile acids deoxycholic acid and lithocholic acid have long been hypothesized as carcinogenic, and they are metabolized from glycine- and taurine-conjugated primary bile acids by gut microbes.^{58,59} Consequently, dietary influences on the microbiome that affect production of secondary bile acids and other carcinogens are particularly important areas of future research.

One study has examined differences in the gut microbes in CRC cases between African Americans and whites. Yazici and colleagues⁶⁰ measured the abundances of sulfidogenic bacteria, including sulfate-reducing bacteria and *B. wadsworthia*, in a well-characterized series of Chicago, IL, CRC cases and endoscopy clinic screening controls. Irrespective of disease status, African Americans exhibited much greater abundances of sulfidogenic bacteria than whites. In addition, African American CRC cases had higher levels of *B. wadsworthia* than African American controls, whereas controls had higher levels of sulfate-reducing bacteria. Although African Americans consumed higher levels of fat and protein than their white counterparts, only a relatively small proportion of the difference in microbial abundance were found to be accounted for by differences in dietary intake in the statistical models. The implication of these results is that an undisclosed racial factor(s) drives differences in microbial abundance.

Causal connections are being sought between obesity and all of the major human cancers, including CRC.^{61,62} Increased consumption of red meat and high-fat and high-glycemic index foods, coupled with reduced levels of physical activity, has fueled an epidemic of obesity and type 2 diabetes at ever-younger ages.⁶³ African Americans have higher rates of diabetes than whites,⁶⁴ more insulin resistance, and more hyperinsulinemia. On the other hand, measures of metabolic syndrome are paradoxically lower because African Americans have paradoxically lower levels of low-density lipoprotein cholesterol, higher high-density lipoprotein cholesterol, lower serum fatty acids, and lower triacylglycerol levels.^{65,66} Although it is not known whether these differences in pancreatic β cell and liver functions are

environmentally or genetically driven (or both), they may play into the racial difference in CRC incidence. Further studies are needed to investigate the links among diabetes, obesity, and CRC in African Americans.

Are Carcinogenic Mechanisms Different in African American CRC?

In addition to risk of CRC, the frequencies of various clinicopathologic features of tumors that arise in African Americans are different from the frequencies found in whites. African Americans have a higher likelihood of a diagnosis in the proximal colon and have a higher prevalence of proximal adenomas than whites.³ These differences are important because, until recently, lesions in the proximal colon were more frequently missed during colonoscopy. African Americans also are often diagnosed at a younger age (median ages, 66 and 70 years for African American men and women compared with 72 and 77 years for white men and women, respectively).⁶⁷ Moreover, African Americans are two times more likely to be diagnosed with CRC before the age of 50 years, which justified the recommendation to begin endoscopic screening at the age of 45 years instead of 50 years. The mechanisms driving early-onset CRC are not known, but a growing body of evidence suggests that they may be different from the mechanisms underlying the older age-of-onset CRCs. Although the field of carcinogenesis in African American CRC has advanced in its efforts to further investigate clinicopathologic differences, our understanding of the molecular pathogenesis of the CRCs that arise in this population group remains in an early stage. However, recent articles have gone beyond the anecdotal evidence and raised questions about the progression of molecular events in CRCs in African Americans.

Similar Frequencies of Microsatellite Instability

A subset of CRCs is driven by a deficiency in DNA MMR genes, which causes a type of genomic instability known as microsatellite instability (MSI). Deficiency of an MMR gene results in increased genomic instability, particularly in microsatellite loci, leading to frequent changes in repeat sequence length in tumor DNA when compared with normal tissue. In the general population, MSI occurs in approximately 15% of CRCs, and it has hereditary and sporadic forms. Patients with Lynch syndrome carry a germline mutation in one of the MMR genes, and MSI develops when the remaining normal copy of the gene is mutated in a cancer precursor cell. The sporadic form of MSI usually develops as a result of DNA methylation of the *MLH1* promoter, and sporadic MSI is associated with more elderly female cases of CRC.⁶⁸ Tumors that exhibit MSI have distinctive clinical features, including increased tumor-infiltrating lymphocytes and a Crohn disease–like inflammatory reaction; an association with right-sided disease; and an association with high-grade tumors with poorly differentiated,

mucinous, or signet-ring phenotypes. Despite the higher grade of MSI tumors, affected individuals have a slightly better prognosis.⁶⁸ Recently, it has been found that MSI tumors are more likely to respond to immune checkpoint therapy,⁶⁹ likely because of the generation of excess neoantigens caused by the increased genomic instability.

Early reports suggested that African Americans had a higher frequency of CRC tumors with MSI.^{70–72} This was an interesting hypothesis because it had the potential to explain the higher frequency of right-sided CRC in African Americans. In furtherance of this idea, Eaton and colleagues⁷³ studied a previously identified polymorphism in 5,10-methylenetetrahydrofolate reductase, whose effect on MSI status of a tumor was mediated by folate status, where the higher the folate intake, the lower the risk of an MSI tumor. Because this protective allele is less common in African Americans, if MSI frequency was increased in this population, then theoretically, it would contribute to an increased incidence of MSI. However, equal or lower frequencies of MSI in African American CRCs were observed in subsequent studies that had larger sample sizes.^{74–76}

A recent meta-analysis of 22 studies with a total of 12,611 CRC patients compared MSI frequencies in African Americans and whites.⁷⁷ Conclusively, no difference in MSI frequencies was found. It is unknown the extent to which biological variables account for differences between studies. MSI is a relatively well-studied CRC subtype; however, it is unknown how much survival of patients with MSI differs by race, which may be important in addressing the health disparity in CRC mortality.

Somatic Mutations in African American CRC

Our understanding of molecular characteristics of microsatellite stable CRCs in African Americans has been lacking in the past because of the limited integration of these communities into population-level studies. This has improved in the past 5 years with studies focusing on chromosomal instability and single-nucleotide variants in African Americans.

Broad copy number variations in African Americans (ie, gains or losses that occur across chromosome arms or entire chromosomes) have been characterized in two studies, both of which have found frequencies of gains and losses to be similar to those seen in previous studies of primarily white patients.^{78,79} Frequent arm-level losses are seen in 1p, 8p, 14q, 15q, 18p, and 18q, whereas arm-level gains are frequently seen in 1q, 7p, 8q, 13q, 19q, 20p, and 20q. However, two other studies^{80,81} found that arm-level changes were different between the two populations ($n = 27$ whites, and $n = 30$ African Americans). An unpublished study from our group (G.J.A. and N.A.E.) examined chromosome-arm copy number alterations but did not see qualitative differences; however, chromosome-arm gains were less frequent in African Americans. Adjustments for factors such as age and stage are needed to account for possible sampling bias in these studies. In addition, larger studies are necessary to determine the extent to

Table 2 Frequency of Mutations in Selected Colorectal Cancer Driver Genes

Study	<i>APC</i> , %	<i>BRAF</i> , %	<i>PIK3CA</i> , %	<i>KRAS</i> , %	<i>TP53</i> , %
Katkoori et al (2009) ⁸⁶					68/137 (49.6)
Sylvester et al (2012) ⁷⁴		6/170 (3.5)		57/170 (33.5)	
Xicola et al (2014) ⁷⁶		16/408 (3.9)		44/192 (22.9)	
Ashktorab et al (2015) ⁸⁴	8/12 (66.7)	1/12 (8.3)	2/12 (16.7)	6/12 (50)	2/12 (16.7)
Guda et al (2015) ⁸⁵	22/29 (75.9)	2/29 (6.9)	5/29 (17.2)	16/29 (55.2)	20/29 (69)
Kang et al (2013) ^{*87}		— (18)	— (28.3)	— (68.5)	

Data are given as number/total (percentage). None of the cited reports claimed that the frequencies of the driver mutations tested in African American colorectal cancers were significantly different from the frequencies reported for white driver mutations. Empty cells indicate that the gene was not tested in the study.

**n* = 67.

—, numerators were not provided in the article.

which clinicopathologic features can be explained by copy number variations.

Different focal alterations may exist in African Americans^{78,79}; however, larger platform-matched studies are necessary to determine a reliable list of affected genes. Despite these advances in exploring copy number variations in African American CRCs, data are still limited. Current studies have relied on small sample sizes (Varadan et al,⁷⁹ *n* = 30 for sequence data and *n* = 12 for array data; Ashktorab and colleagues,⁸⁰ *n* = 15), and they were not powered to account for differences in tumor location, stage, or differentiation status.

Genomic instability has also been noted in patient samples with elevated microsatellite alterations at selected tetranucleotide repeats (EMASTs). This EMAST instability phenotype has been described to be present in 60% of sporadic CRC cases, specifically in MSI, but also often in non-MSI cases.⁸² In a cohort of rectal cancer patients (*n* = 147, 26% African American), the EMAST phenotype was more frequent in African Americans, and it was associated with advanced stage.⁸³ Because EMAST has been described in both MSI and microsatellite stable tumors, the etiological basis of EMAST may be heterogeneous. Further study is needed to understand the relationship of this instability to tumor progression and outcome in African American CRC.

DNA sequencing studies have been used to investigate somatic mutations in African American CRCs to determine the extent to which genes involved in tumor development are different in African American colorectal carcinogenesis.^{84,85} For the known cancer driver genes (*KRAS*, *BRAF*, *TP53*, *PIK3CA*, and *APC*) (Figure 2), frequencies of somatic mutations have been reported for relatively limited sample series (Table 2). Significant differences were not reported. Several groups have focused on the identification of novel driver genes that might explain features of the cancer health disparity. Ashktorab et al⁸⁴ identified single-nucleotide variants in the CRC initiator *APC* that were unique to African Americans. Guda et al⁸⁵ concentrated their efforts on identifying novel genes involved in advanced CRCs in African Americans. To do so, they sequenced 31 late-stage microsatellite stable CRCs from Case Medical Center (Cleveland, OH) and identified a 15-gene set that they followed up in a series of 129 African

American cases in a replication stage. Most frequently mutated in this gene set was *EPHA6*, a member of the ephrin receptor tyrosine kinase family that has been previously implicated in CRC development.⁸⁸ Another frequently mutated gene of interest was *CHD5*, a chromatin-remodeling protein that was also frequently mutated in a study by our group (G.J.A. and N.A.E., unpublished data). This gene set was used to determine differences in survival. It predicted poorer survival, especially in later-stage African American CRCs (*n* = 66).⁸⁹ Large multi-institutional studies are needed to confirm and extend these results.

Epigenetic Changes in African American CRC

There has been an increasing interest in changes to gene expression and DNA methylation in CRC, with several groups comparing African American CRCs with tumors from whites. An early study⁹⁰ (*n* = 102, 50% African American) used methylation-specific PCR to look at methylation in promoters of a candidate cancer gene panel of 14 genes. Three genes were found to be hypermethylated in African Americans compared with white samples. Among them was *CHD5*, a tumor suppressor that was identified as a recurrently mutated gene that may be important in African American CRC development.⁸⁵ This epigenetic silencing was further studied by Fatemi et al⁹¹ (*n* = 18 adenomas, and *n* = 6 healthy normal samples), who validated the down-regulation of *CHD5* in adenoma samples and noted that this may be an early event in CRC tumor progression of African Americans. In addition, the promoters of *ICAM5* (part of the intercellular adhesion molecule family) and *GPNMB* (a glycoprotein) were found to be hypermethylated in African American CRCs in the study by Mokarram et al.⁹⁰

Further studies have used more comprehensive technologies to discover more genes with DNA hypermethylation in African American CRC. The development of methylation microarrays, such as Illumina's Infinium HumanMethylation27 and HumanMethylation450 BeadChip arrays (Illumina, San Diego, CA), and bisulfite sequencing techniques allow scientists to look genome wide for differential DNA methylation. Using microarray technology, Ashktorab and colleagues⁹² found 16 genes with consistent promoter

hypermethylation in a small cohort of African Americans ($n = 12$ CRCs, $n = 8$ adenomas, and $n = 2$ normal colon samples). Among these genes, *ICAM5* and *DCC* were previously identified, which was studied by Mokarram et al⁹⁰ but not found to be differentially methylated. In addition, the promoter of *EVL* was found to be more highly methylated in their African American CRC cohort than reported in other white cohorts. Well-known tumor suppressors were also included in this list, including *APC* and *PTEN*.

Reduced representation bisulfite sequencing gives an even more granular look at the epigenome by increasing the number of CpGs covered into the millions. Ashktorab et al⁹³ sought to identify potential biomarkers for African American CRC by identifying novel hypermethylated genes using reduced representation bisulfite sequencing. This study elucidated four genes that were hypermethylated, including *EID3*, *GPR75*, *GAS7*, and *BMP3*. The latter two of these genes are in the insulin and transforming growth factor- β network, and other G-protein-coupled receptors are within this network as well. This interesting result connects tumorigenesis with insulin signaling that is affected in diabetes. Other studies have shown that diabetes can increase an individual's risk for CRC⁹⁴; however, the biological basis of this association is not yet known. In another study from the same group,⁹⁵ additional CpG islands were identified as hypermethylated in African American CRC, including *L3MBTL1*, *NKX6-2*, *PREX1*, *TRAF7*, *PRDM14*, and *NEFM*. This small study focused on increased methylation from normal to adenoma to malignancy ($n = 5$ CRCs, $n = 2$ adenomas, $n = 1$ blood, and $n = 1$ normal colon). These genes map to pathways often dysregulated during cancer development (namely, WNT/ β -catenin, phosphatidylinositol 3-kinase, AKT, vascular endothelial growth factor, and Janus-activating kinase/STAT3 signaling pathways) (Figure 2). The methylation of these genes was specific to CRCs and not found in adenomas.

Another study⁹⁶ took a comparative approach, comparing DNA methylation in African American and white CRCs ($n = 6$ African Americans, and $n = 7$ whites). Several differentially methylated genes were miRNAs, two of which (ie, miR-9 and miR-124) have previously been implicated in CRC development.^{97–99} Among the differentially methylated miRNAs was miR-124-3p, which was hypermethylated in African American CRCs compared with white CRCs. RNA-sequencing analysis found that two targets of this miRNA (ie, *POLR2B* and *CYP11B1*) were among the up-regulated genes in these cases.

These studies are limited by their sample size of cancer patients, because most incorporated <10 samples into their genome-wide analyses. In addition, integration of methylation data with clinicopathologic and molecular features is needed. For example, it is known that DNA methylation and expression profiles differ in CRCs with MSI¹⁰⁰; therefore, stratifying analyses based on this criterion may remove some heterogeneity. Notably, there was no overlap in the

genes identified in different studies, which raises the question of reproducibility.

CRC-Specific Gene Dysregulation

A recent landmark article based on European-ancestry CRC cases described four major expression-based CRC subtypes, referred to as consensus molecular subtypes (CMSs).¹⁰⁰ CMS1 closely represents the MSI-immune CRCs, with *BRAF* mutations, hypermutation, a hypermethylation phenotype, and immune cell infiltration. CMS2 represents the canonical CRC subtype, driven by WNT signaling and *MYC* activation and containing excess copy number alterations. CMS3 represents metabolic CRC, driven by *KRAS* mutations and associated with metabolic dysregulation and higher genome stability. Finally, CMS4 represents mesenchymal CRC, associated with stromal infiltration, transforming growth factor- β activation, and angiogenesis markers. These subtypes are important because CMS1 is associated with worse survival after relapse and CMS4 is associated with worse relapse-free and overall survival.

In studies of African American CRC, this area experiences some of the same limitations (ie, reproducibility and covariate availability issues) as others when looking at its impact on the health disparity. Two studies compared gene expression in African American and white patients with CRCs.^{96,101} These studies identified 142 and 10 dysregulated genes, respectively, of which no genes were identified in both studies. The larger of the two studies, by Jovov and colleagues,¹⁰¹ validated expression of their 10 genes in an independent set of patients ($n = 86$, 50% African American). It would be interesting to reanalyze these data in light of the CMS subtype classification system,¹⁰⁰ including the CMS1 subtype that is associated with MSI status.

In addition, two studies have focused on miRNA expression. Bovell et al¹⁰² ($n = 106$ African Americans, and $n = 239$ whites) found high miR-203 expression to be associated with poor survival in early-stage African American CRCs, whereas high miR-181b expression was associated with poor survival in stage III CRCs from African Americans. The prognostic value differed from the white patients in the study, suggesting that expression profiles may have a different prognostic value, depending on a patient's race and the stage of the disease. Li et al¹⁰³ found five miRNAs whose expression levels differed by race in their cohort ($n = 30$ African Americans, and $n = 31$ whites). Specifically, miR-182 was up-regulated in African American CRCs compared with white CRCs, and two potential miR-182 targets (*FOXO1* and *FOXO3A*) were expressed at lower levels in African American CRCs.

Both expression of genes and expression of regulatory molecules, such as miRNAs, may act as possible prognostic biomarkers for CRCs in African Americans. Replication studies are necessary to validate the above findings. In addition, application of molecular pathological

epidemiology,¹⁰⁴ integrating information from multiple sources, such as CMS status, clinicopathologic features, and environmental/behavioral factors, would result in better design of future studies.

The Continuing Problem of CRC Mortality in African Americans

As previously mentioned,² African Americans have the highest mortality rate of CRC of any ethnic group in the United States. This disparity has been noted in previous reviews,^{105–107} which looked at behaviors, stage of tumor, treatment, and socioeconomic status as potential explanations. Some of this difference can be explained by tumor stage and socioeconomic status, but the disparity remains even after accounting for tumor stage at diagnosis and after adjusting for socioeconomic status, comorbidities, and treatment.^{4,108,109} The effect of body mass index on survival was assessed, and although it had an effect on survival, it was determined not to contribute to the disparity.¹¹⁰

The rate of mortality for CRC has decreased since the early 2000s; however, the mortality rate of African Americans is still 35% higher than that of whites (Figure 1B). The rate of decrease in mortality has improved as well, with both African Americans and whites having annual percentage changes in rate of -2.5% to 3%. Increased endoscopic screening by African Americans has contributed to the decrease in mortality.

Several biomarkers have been proposed to enable a more accurate prognosis for African American CRC patients. Some, including nuclear accumulation of p53^{111,112} and mucin 1,¹¹³ have been unsuccessful. Others have been weak markers for prognosis, such as Bcl2^{112,114} (whose lack of expression was weakly associated with survival, particularly in distal tumors) and p27^{kip1}¹¹⁵ (whose lowered expression was associated with worse survival in African Americans and whites but only in stage III CRCs).

Jones et al¹¹⁶ identified a polymorphism in the glutathione S-transferase gene (*GSTP1*) that is associated with a decreased risk of death for the genotype Ile/Val or Val/Val. This effect was more pronounced in patients who underwent chemotherapy. However, the genotype frequency did not vary by race, and was determined not to contribute to the disparity.

Additional work was done to identify if somatic gene mutations may predict a CRC patient outcome.⁸⁷ This study tested for *KRAS*, *BRAF*, and *PIK3CA* mutations as well as MSI status. They found that *KRAS* mutations were more frequent in African Americans and were associated with advanced stage in these patients. *PIK3CA* mutations were associated with decreased survival when adjusted for MSI, education, and income; however, the CI for the hazard ratio estimate was wide, limiting the interpretation of this piece of data. The authors suggest that the different frequency of somatic alterations may explain some of the differences in survival, a gap that needs to be addressed in future research.

Overall, despite research that has given us valuable knowledge about factors that have effects on CRC mortality, we still know relatively little about the molecular mechanisms underpinning why African Americans with CRC are more likely to die from the disease than other ethnic groups. More work is necessary to determine the effectiveness of current treatments in this population. In addition, differences in tumor progression markers may explain some of the differences in mortality⁸⁹; however, further research is needed to determine whether validated prognostic biomarkers can be developed.

References

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. *CA Cancer J Clin* 2016, 66:7–30
2. Siegel R, DeSantis C, Jemal A: Colorectal cancer statistics, 2014. *CA Cancer J Clin* 2014, 64:104–117
3. Dimou A, Syrigos KN, Saif MW: Disparities in colorectal cancer in African-Americans vs whites: before and after diagnosis. *World J Gastroenterol* 2009, 15:3734–3743
4. Alexander DD, Waterbor J, Hughes T, Funkhouser E, Grizzle W, Manne U: African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. *Cancer Biomark* 2007, 3:301–313
5. Agrawal S, Bhupinderjit A, Bhutani MS, Boardman L, Nguyen C, Romero Y, Srinivasan R, Figueroa-Moseley C: Colorectal cancer in African Americans. *Am J Gastroenterol* 2005, 100:515–523
6. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM: American College of Gastroenterology guidelines for colorectal cancer screening 2009. *Am J Gastroenterol* 2009, 104: 739–750
7. Carethers JM: Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. *Dig Dis Sci* 2015, 60:711–721
8. Powe BD, Faulkenberry R, Harmond L: A review of intervention studies that seek to increase colorectal cancer screening among African Americans. *Am J Health Promot* 2010, 25:92–99
9. Ashktorab H, Vilmenay K, Brim H, Laiyemo AO, Kibreab A, Nouriaie M: Colorectal cancer in young African Americans: is it time to revisit guidelines and prevention? *Dig Dis Sci* 2016, 61: 3026–3030
10. Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000, 343: 78–85
11. Kupfer SS, Ellis NA: Hereditary colorectal cancer. Edited by Coleman WB, Tsongalis GJ. In *Molecular Basis of Human Cancer*. New York, NY: Springer, 2017, pp. 381–400
12. Krausova M, Korinek V: Wnt signaling in adult intestinal stem cells and cancer. *Cell Signal* 2014, 26:570–579
13. Poulsen ML, Bisgaard ML: MUTYH associated polyposis (MAP). *Curr Genomics* 2008, 6:420–435
14. Jiao S, Peters U, Berndt S, Brenner H, Butterbach K, Caan BJ, Carlson CS, Chan AT, Chang-Claude J, Chanock S, Curtis KR, Duggan D, Gong J, Harrison TA, Hayes RB, Henderson BE, Hoffmeister M, Kolonel LN, Le Marchand L, Potter JD, Rudolph A, Schoen RE, Seminara D, Slaterry ML, White E, Hsu L: Estimating the heritability of colorectal cancer. *Hum Mol Genet* 2014, 23: 3898–3905
15. Weber TK, Chin HM, Rodriguez-Bigas M, Keitz B, Gilligan R, O'Malley L, Urf E, Diba N, Pazik J, Petrelli NJ: Novel hMLH1 and

- hMSH2 germline mutations in African Americans with colorectal cancer. *JAMA* 1999, 281:2316–2320
16. Inra JA, Steyerberg EW, Grover S, McFarland A, Syngal S, Kastrinos F: Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing. *Genet Med* 2015, 17:1–7
 17. Guindalini RSC, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, Raymond V, Stoffel E, Hall M, Llor X, Ukaegbu CI, Solomon I, Weitzel J, Kalady M, Blanco A, Terdiman J, Shuttlesworth GA, Lynch PM, Hampel H, Lynch HT, Jenkins MA, Olopade OI, Kupfer SS: Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. *Gastroenterology* 2015, 149:1446–1453
 18. Peters U, Bien S, Zubair N: Genetic architecture of colorectal cancer. *Gut* 2015, 31:1623–1636
 19. Wang H, Haiman CA, Burnett T, Fortini BK, Kolonel LN, Henderson BE, Signorello LB, Blot WJ, Keku TO, Berndt SI, Newcomb PA, Pande M, Amos CI, West DW, Casey G, Sandler RS, Haile R, Stram DO, Le Marchand L: Fine-mapping of genome-wide association study-identified risk loci for colorectal cancer in African Americans. *Hum Mol Genet* 2013, 22:5048–5055
 20. Kupfer SS, Anderson JR, Hooker S, Skol A, Kittles RA, Keku TO, Sandler RS, Ellis NA: Genetic heterogeneity in colorectal cancer associations between African and European Americans. *Gastroenterology* 2010, 139:1677–1685
 21. Kupfer SS, Skol AD, Hong E, Ludvik A, Kittles RA, Keku TO, Sandler RS, Ellis NA: Shared and independent colorectal cancer risk alleles in TGF β -related genes in African and European Americans. *Carcinogenesis* 2014, 35:2025–2030
 22. Lemire M, Qu C, Loo LWM, Zaidi SHE, Wang H, Berndt SI, et al: A genome-wide association study for colorectal cancer identifies a risk locus in 14q23.1. *Hum Genet* 2015, 134:1249–1262
 23. Wang H, Burnett T, Kono S, Haiman CA, Iwasaki M, Wilkens LR, et al: Trans-ethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A. *Nat Commun* 2014, 5:4613
 24. Wang H, Schmit SL, Haiman CA, Keku TO, Kato I, Palmer JR, van den Berg D, Wilkens LR, Burnett T, Conti DV, Schumacher FR, Signorello LB, Blot WJ, Zanetti KA, Harris C, Pande M, Berndt SI, Newcomb PA, West DW, Haile R, Stram DO, Figueiredo JC, Le Marchand L, Le Marchand L: Novel colon cancer susceptibility variants identified from a genome-wide association study in African Americans. *Int J Cancer* 2017, 140:2728–2733
 25. Zeng C, Matsuda K, Jia WH, Chang J, Kweon SS, Xiang YB, et al: Identification of susceptibility loci and genes for colorectal cancer risk. *Gastroenterology* 2016, 150:1633–1645
 26. Holick MF, Chen TC: Vitamin D deficiency: a worldwide problem with health consequences. *Am J Clin Nutr* 2008, 87:1080S–1086S
 27. Giovannucci E: Vitamin D and cancer incidence in the Harvard cohorts. *Ann Epidemiol* 2009, 19:84–88
 28. Woolcott CG, Wilkens LR, Nomura AM, Horst RL, Goodman MT, Murphy SP, Henderson BE, Kolonel LN, Le Marchand L: Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. *Cancer Epidemiol Biomarkers Prev* 2010, 19:130–134
 29. Fichera A, Little N, Dougherty U, Mustafi R, Cerda S, Li YC, Delgado J, Arora A, Campbell LK, Joseph L, Hart J, Noffsinger A, Bissonnette M: A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. *J Surg Res* 2007, 142:239–245
 30. Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW: Racial pigmentation and the cutaneous synthesis of vitamin-D. *Arch Dermatol* 1991, 127:536–538
 31. Grant WB, Peiris AN: Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans. *Dermatoendocrinol* 2012, 4:85–94
 32. Fiscella K, Winters P, Tancredi D, Hendren S, Franks P: Racial disparity in death from colorectal cancer: does vitamin D deficiency contribute? *Cancer* 2011, 117:1061–1069
 33. Zheng XE, Lipka S, Li T, Shahzad G, Levine E, Vlacancich R, Takeshige U, Mustacchia P: The relationship of vitamin D status, smoking, and colorectal adenoma: a retrospective study in an ethnically diverse community. *J Steroid Biochem Mol Biol* 2013, 136:280–283
 34. LePane CA, Singh G, Spanier-Stiasny JA, Svinarich DM, Rasansky RJ, Hoffman SMJ: Implications of serum 25-hydroxyvitamin D on the prevalence of neoplastic polyps: a cross-sectional study. *Gastroenterol Res* 2011, 4:43–50
 35. Ashktorab H, Nguza B, Fatemi M, Nouraei M, Smoot DT, Schäffer AA, Kupfer SS, Camargo CA Jr, Brim H: Case-control study of vitamin D, dickkopf homolog 1 (DKK1) gene methylation, VDR gene polymorphism and the risk of colon adenoma in African Americans. *PLoS One* 2011, 6:e25314
 36. Ahmad II, Trikudanathan G, Feinn R, Anderson JC, Nicholson M, Lowe S, Levine JB: Low serum vitamin D: a surrogate marker for advanced colon adenoma? *J Clin Gastroenterol* 2016, 50:644–648
 37. Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, Bostick RM, Ivanova A, Cole BF, Ahnen DJ, Beck GJ, Bresalier RS, Burke CA, Church TR, Cruz-Correa M, Figueiredo JC, Goodman M, Kim AS, Robertson DJ, Rothstein R, Shaikat A, Seabrook ME, Summers RW: A trial of calcium and vitamin D for the prevention of colorectal adenomas. *N Engl J Med* 2015, 373:1519–1530
 38. Slattey ML, Herrick J, Wolff RK, Caan BJ, Potter JD, Sweeney C: CDX2 VDR polymorphism and colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2007, 16:2752–2755
 39. Kupfer SS, Anderson JR, Ludvik AE, Hooker S, Skol A, Kittles RA, Keku TO, Sandler RS, Ruiz-Ponte C, Castellvi-Bel S, Castells A, Carracedo A, Ellis NA: Genetic associations in the vitamin D receptor and colorectal cancer in African Americans and Caucasians. *PLoS One* 2011, 6:e26123
 40. Pibiri F, Kittles RA, Sandler RS, Keku TO, Kupfer SS, Xicola RM, Llor X, Ellis NA: Genetic variation in vitamin D-related genes and risk of colorectal cancer in African Americans. *Cancer Causes Control* 2014, 25:561–570
 41. Hiraki LT, Qu C, Hutter CM, Baron JA, Berndt SI, Bézieau S, et al: Genetic predictors of circulating 25-hydroxyvitamin D and risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2013, 22:2037–2046
 42. Barry EL, Peacock JL, Rees JR, Bostick RM, Robertson DJ, Bresalier RS, Baron JA: Vitamin D receptor genotype, vitamin D₃ supplementation, and risk of colorectal adenomas. *JAMA Oncol* 2016, 10:e0124339
 43. Alleyne D, Witonsky DB, Mapes B, Nakagome S, Sommars M, Hong E, Muckala KA, Di Rienzo A, Kupfer SS: Colonic transcriptional response to 1 α ,25(OH)₂ vitamin D₃ in African- and European-Americans. *J Steroid Biochem Mol Biol* 2017, 168:49–59
 44. Huler I, Gamazon ER, Skol AD, Xicola RM, Llor X, Onel K, Ellis NA, Kupfer SS: Enrichment of inflammatory bowel disease and colorectal cancer risk variants in colon expression quantitative trait loci. *BMC Genomics* 2015, 16:138
 45. Moradi T, Delfino RJ, Bergström SR, Yu ES, Adami HO, Yuen J: Cancer risk among Scandinavian immigrants in the US and Scandinavian residents compared with US whites, 1973–89. *Eur J Cancer Prev* 1998, 7:117–125
 46. Flood DM, Weiss NS, Cook LS, Emerson JC, Schwartz SM, Potter JD: Colorectal cancer incidence in Asian migrants to the United States and their descendants. *Cancer Causes Control* 2000, 11:403–411
 47. Willett WC, Stampfer MJ: Current evidence on healthy eating. *Annu Rev Public Health* 2013, 34:77–95
 48. Potter JD: Nutritional epidemiology: there's life in the old dog yet! *Cancer Epidemiol Biomarkers Prev* 2015, 24:323–330
 49. Ananthakrishnan AN, Du M, Berndt SI, Brenner H, Caan BJ, Casey G, Chang-Claude J, Duggan D, Fuchs CS, Gallinger S, Giovannucci EL, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hou L, Hsu L, Jenkins MA, Kraft P, Ma J, Nan H, Newcomb PA, Ogino S, Potter JD,

- Seminara D, Slattery ML, Thornquist M, White E, Wu K, Peters U, Chan AT: Red meat intake, NAT2, and risk of colorectal cancer: a pooled analysis of 11 studies. *Cancer Epidemiol Biomarkers Prev* 2015, 24:198–205
50. Chan DSM, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, Norat T: Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. *PLoS One* 2011, 6:e20456
 51. Satia JA, Tseng M, Galanko JA, Martin C, Sandler RS: Dietary patterns and colon cancer risk in whites and African Americans in the North Carolina Colon Cancer Study. *Nutr Cancer* 2009, 61:179–193
 52. Williams CD, Satia JA, Adair LS, Stevens J, Galanko J, Keku TO, Sandler RS: Dietary patterns, food groups, and rectal cancer risk in whites and African-Americans. *Cancer Epidemiol Biomarkers Prev* 2009, 18:1552–1561
 53. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE: Metagenomic analysis of the human distal gut microbiome. *Science* 2006, 312:1355–1359
 54. Hooper LV, Gordon JI: Commensal host-bacterial relationships in the gut. *Science* 2001, 292:1115–1118
 55. Drewes JL, Housseau F, Sears CL: Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy. *Br J Cancer* 2016, 115:273–280
 56. Sears CL, Garrett WS: Microbes, microbiota, and colon cancer. *Cell Host Microbe* 2014, 15:317–328
 57. O'Keefe SJD, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, Posma JM, Kinross J, Wahl E, Ruder E, Vippera K, Naidoo V, Mtshali L, Tims S, Puylaert PGB, DeLany J, Krasinskas A, Benefiel AC, Kaseb HO, Newton K, Nicholson JK, de Vos WM, Gaskins HR, Zoetendal EG: Fat, fibre and cancer risk in African Americans and rural Africans. *Nat Commun* 2015, 6:6342
 58. Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB: Consequences of bile salt biotransformations by intestinal bacteria. *Gut Microbes* 2016, 7:22–39
 59. Tsuei J, Chau T, Mills D, Wan Y-JY: Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. *Exp Biol Med* (Maywood) 2014, 239:1489–1504
 60. Yazici C, Wolf PG, Kim H, Cross T-WL, Vermillion K, Carroll T, Augustus GJ, Mutlu E, Tussing-Humphreys L, Braunschweig C, Xicola RM, Jung B, Llor X, Ellis NA, Gaskins HR: Race-dependent association of sulfidogenic bacteria with colorectal cancer. *Gut* 2017, 66:1983–1994
 61. Goodwin PJ, Stambolic V: Impact of the obesity epidemic on cancer. *Annu Rev Med* 2015, 66:281–296
 62. Iyengar NM, Hudis CA, Dannenberg AJ: Obesity and cancer: local and systemic mechanisms. *Annu Rev Med* 2015, 66:297–309
 63. Pereira MA, Kartashov AI, Ebbeling CB, Van Horn L, Slattery ML, Jacobs PDR, Ludwig DS: Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. *Lancet* 2005, 365:36–42
 64. Harris MI: Noninsulin-dependent diabetes mellitus in black and white Americans. *Diabetes Metab Rev* 1990, 6:71–90
 65. Tsai CJ, Giovannucci EL: Hyperinsulinemia, insulin resistance, vitamin D, and colorectal cancer among whites and African Americans. *Dig Dis Sci* 2012, 57:2497–2503
 66. Gaillard T, Schuster D, Osei K: Metabolic syndrome in black people of the African diaspora: the paradox of current classification, definition and criteria. *Ethn Dis* 2009, 19: S2-1-7
 67. Desantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A: Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. *CA Cancer J Clin* 2016, 66:290–308
 68. Vilar E, Gruber SB: Microsatellite instability in colorectal cancer: the stable evidence. *Nat Rev Clin Oncol* 2010, 7:153–162
 69. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr: PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med* 2015, 372:2509–2520
 70. Ashktorab H, Smoot DT, Carethers JM, Rahmanian M, Kittles R, Vosganian G, Doura M, Nidhiry E, Naab T, Momen B, Shakhani S, Giardiello FM: High incidence of microsatellite instability in colorectal cancer from African Americans. *Clin Cancer Res* 2003, 9:1112–1117
 71. Ashktorab H, Smoot DT, Farzanmehr H, Fidelia-Lambert M, Momen B, Hyland L, Iacosozio-Dononue C, Carethers JM, Goel A, Boland CR, Giardiello FM: Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. *Int J Cancer* 2005, 116:914–919
 72. Brim H, Mokarram P, Naghibalhossaini F, Saberi-Firooz M, Al-Mandhari M, Al-Mawaly K, Al-Mjeni R, Al-Sayegh A, Raeburn S, Lee E, Giardiello F, Smoot DT, Vilkin A, Boland CR, Goel A, Hafezi M, Nouraei M, Ashktorab H: Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. *Mol Cancer* 2008, 7:68
 73. Eaton AM, Sandler R, Carethers JM, Millikan RC, Galanko J, Keku TO: 5,10-Methylenetetrahydrofolate reductase 677 and 1298 polymorphisms, folate intake, and microsatellite instability in colon cancer. *Cancer Epidemiol Biomarkers Prev* 2005, 14:2023–2029
 74. Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling RV, Olugbile S, Polite BN, Olopade OI: Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. *Clin Cancer Res* 2012, 18:350–359
 75. Carethers JM, Murali B, Yang B, Doctolero RT, Tajima A, Basa R, Julieta Smith E, Lee M, Janke R, Ngo T, Tejada R, Ji M, Kinseth M, Cabrera BL, Miyai K, Keku TO, Martin CF, Galanko JA, Sandler RS, McGuire KL: Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. *PLoS One* 2014, 9:e100461
 76. Xicola RM, Gagnon M, Clark JR, Carroll T, Gao W, Fernandez C, Mijic D, Rawson JB, Janoski A, Pusatcioglu CK, Rajaram P, Gluskin AB, Regan M, Chaudhry V, Abcarian H, Blumetti J, Cintron J, Melson J, Xie H, Guzman G, Emmadi R, Alagiozian-Angelova V, Kupfer SS, Braunschweig C, Ellis NA, Llor X: Excess of proximal microsatellite-stable colorectal cancer in African Americans on a multiethnic study. *Clin Cancer Res* 2014, 20:4962–4970
 77. Ashktorab H, Ahuja S, Kannan L, Llor X, Ellis NA, Xicola RM, Laiyemo AO, Carethers JM, Brim H, Nouraei M: A meta-analysis of MSI frequency and race in colorectal cancer. *Oncotarget* 2016, 7: 34546–34557
 78. Ashktorab H, Schäffer AA, Daramipouran M, Smoot DT, Lee E, Brim H: Distinct genetic alterations in colorectal cancer. *PLoS One* 2010, 5:e8879
 79. Varadan V, Singh S, Nosrati A, Ravi L, Lutterbaugh J, Barnholtz-Sloan JS, Markowitz SD, Willis JE, Guda K: ENVE: a novel computational framework characterizes copy-number mutational landscapes in African American colon cancers. *Genome Med* 2015, 7:69
 80. Brim H, Lee E, Abu-Asab MS, Chaouchi M, Razjouyan H, Namin H, Goel A, Schäffer AA, Ashktorab H: Genomic aberrations in an African American colorectal cancer cohort reveals a MSI-specific profile and chromosome X amplification in male patients. *PLoS One* 2012, 7:e40392
 81. Brim H, Abu-Asab MS, Nouraei M, Salazar J, DeLeo J, Razjouyan H, Mokarram P, Schäffer AA, Naghibhossaini F, Ashktorab H: An integrative CGH, MSI and candidate genes methylation analysis of colorectal tumors. *PLoS One* 2014, 9:e82185
 82. Haugen AC, Goel A, Yamada K, Marra G, Nguyen TP, Nagasaka T, Kanazawa S, Koike J, Kikuchi Y, Zhong X, Arita M, Shibuya K, Oshimura M, Hemmi H, Boland CR, Koi M: Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. *Cancer Res* 2008, 68:8465–8472
 83. Devaraj B, Lee A, Cabrera BL, Miyai K, Luo L, Ramamoorthy S, Keku T, Sandler RS, McGuire KL, Carethers JM: Relationship of

- EMAST and microsatellite instability among patients with rectal cancer. *J Gastrointest Surg* 2010, 14:1521–1528
84. Ashktorab H, Daremipouran M, Devaney J, Varma S, Rahi H, Lee E, Shokrani B, Schwartz R, Nickerson ML, Brim H: Identification of novel mutations by exome sequencing in African American colorectal cancer patients. *Cancer* 2015, 121:34–42
 85. Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JKV, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE: Novel recurrently mutated genes in African American colon cancers. *Proc Natl Acad Sci U S A* 2015, 112:1149–1154
 86. Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, Bumpers H, Grizzle WE, Manne U: Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. *Clin Cancer Res* 2009, 15:2406–2416
 87. Kang M, Shen XJ, Kim S, Araujo-Perez F, Galanko JA, Martin CF, Sandler RS, Keku TO: Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. *Cancer Biomark* 2013, 13:359–366
 88. Boyd AW, Bartlett PF, Lackmann M: Therapeutic targeting of EPH receptors and their ligands. *Nat Rev Drug Discov* 2014, 13:39–62
 89. Wang Z, Li L, Guda K, Chen Z, Barnholtz-Sloan J, Park YS, Markowitz SD, Willis J: Adverse clinical outcome associated with mutations that typify African American colorectal cancers. *J Natl Cancer Inst* 2016, 108: pii: djw164
 90. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberifiroozi M, Nouraie M, Green R, Lee E, Smoot DT, Ashktorab H: Distinct high-profile methylated genes in colorectal cancer. *PLoS One* 2009, 4:e7012
 91. Fatemi M, Paul TA, Brodeur GM, Shokrani B, Brim H, Ashktorab H: Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. *Cancer* 2014, 120:172–180
 92. Ashktorab H, Rahi H, Wansley D, Varma S, Shokrani B, Lee E, Daremipouran M, Laiyemo A, Goel A, Carethers JM, Brim H: Toward a comprehensive and systematic methylome signature in colorectal cancers. *Epigenetics* 2013, 8:807–815
 93. Ashktorab H, Daremipouran M, Goel A, Varma S, Leavitt R, Sun X, Brim H: DNA methylome profiling identifies novel methylated genes in African American patients with colorectal neoplasia. *Epigenetics* 2014, 9:503–512
 94. Peeters PJHL, Bazelier MT, Leufkens HGM, de Vries F, De Bruin ML: The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. *Diabetes Care* 2015, 38:495–502
 95. Ashktorab H, Shakoori A, Zarnogi S, Sun X, Varma S, Lee E, Shokrani B, Laiyemo AO, Washington K, Brim H: Reduced representation bisulfite sequencing determination of distinctive DNA hypermethylated genes in the progression to colon cancer in African Americans. *Gastroenterol Res Pract* 2016, 2016:2102674
 96. Wang X, Ji P, Zhang Y, LaComb JF, Tian X, Li E, Williams JL: Aberrant DNA methylation: implications in racial health disparity. *PLoS One* 2016, 11:1–16
 97. Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama K, Akao Y: MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. *Cancer Lett* 2015, 363:17–27
 98. Oberg AL, French AJ, Sarver AL, Subramanian S, Morlan BW, Riska SM, Borralho PM, Cunningham JM, Boardman LA, Wang L, Smyrk TC, Asmann Y, Steer CJ, Thibodeau SN: miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. *PLoS One* 2011, 6:e20465
 99. Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA, Skotheim RI: MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. *Neoplasia* 2012, 14: 868–879
 100. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al: The consensus molecular subtypes of colorectal cancer. *Nat Med* 2015, 21:1350–1356
 101. Jovov B, Araujo-Perez F, Sigel CS, Stratford JK, McCoy AN, Yeh JJ, Keku T: Differential gene expression between African American and European American colorectal cancer patients. *PLoS One* 2012, 7: e30168
 102. Bovell LC, Shanmugam C, Putcha BDK, Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE, Manne U: The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. *Clin Cancer Res* 2013, 19:3955–3965
 103. Li E, Ji P, Ouyang N, Zhang Y, Wang XY, Rubin DC, Davidson NO, Bergamaschi R, Shroyer KR, Burke S, Zhu W, Williams JL: Differential expression of miRNAs in colon cancer between African and Caucasian Americans: implications for cancer racial health disparities. *Int J Oncol* 2014, 45:587–594
 104. Ogino S, Chan AT, Fuchs CS, Giovannucci E: Molecular pathologic epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. *Gut* 2011, 3:397–411
 105. Rabeneck L, El-Serag H, Davila J, Sandler R: Outcomes of colorectal cancer in the United States: no change in survival (1986-1997). *Am J Gastroenterol* 2003, 98:471–477
 106. James AS, Campbell MK, DeVellis B, Reedy J, Carr C, Sandler RS: Health behavior correlates among colon cancer survivors: NC STRIDES baseline results. *Am J Health Behav* 2006, 30:720–730
 107. Polite BN, Dignam JJ, Olopade OI: Colorectal cancer model of health disparities: understanding mortality differences in minority populations. *J Clin Oncol* 2006, 24:2179–2187
 108. Alexander D, Chatla C, Funkhouser E, Meleth S, Grizzle WE, Manne U: Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. *Cancer* 2004, 101:66–76
 109. Alexander D, Jhala N, Chatla C, Steinhauer J, Funkhouser E, Coffey CS, Grizzle WE, Manne U: High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. *Cancer* 2005, 103:2163–2170
 110. Hines RB, Shanmugam C, Waterbor JW, McGwin G, Funkhouser E, Coffey CS, Posey J, Manne U: Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. *Cancer* 2009, 115:5798–5806
 111. Manne U, Weiss HL, Myers RB, Danner OK, Moron C, Srivastava S, Grizzle WE: Nuclear accumulation of p53 in colorectal adenocarcinoma prognostic importance differs with race and location of the tumor. *Cancer* 1998, 83:2456–2467
 112. Grizzle WE, Manne U, Weiss HL, Jhala N, Talley L: Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 and p27kip-1. *Int J Cancer* 2002, 97:403–409
 113. Manne U, Weiss HL, Grizzle WE: Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. *Clin Cancer Res* 2000, 6:4017–4025
 114. Manne U, Weiss HL, Grizzle WE: Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. *Int J Cancer* 2000, 89:423–430
 115. Manne U, Jhala NC, Jones J, Weiss HL, Chatla C, Meleth S, Suarez-Cuervo C, Grizzle WE: Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage. *Clin Cancer Res* 2004, 10:1743–1752
 116. Jones BA, Christensen AR, Wise JP, Yu H: Glutathione S-transferase polymorphisms and survival in African-American and white colorectal cancer patients. *Cancer Epidemiol* 2009, 33:249–256